<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03075397</url>
  </required_header>
  <id_info>
    <org_study_id>16 8193</org_study_id>
    <secondary_id>2016-A01025-46</secondary_id>
    <nct_id>NCT03075397</nct_id>
  </id_info>
  <brief_title>VIH-1 Colo-rectal Transmission by Infected Semen Cells and Effects of Seminal Plasma ex Vivo (CellspermVIH)</brief_title>
  <acronym>CellspermVIH</acronym>
  <official_title>VIH-1 Colo-rectal Transmission by Infected Semen Cells and Effects of Seminal Plasma ex Vivo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of our project is to determine the infected seminal cell types and the
      molecular mechanisms involved in HIV cell-associated transmission in the colo-rectal mucosa,
      using conditions as close as possible to real life, i.e. seminal leukocytes and seminal
      plasma from HIV-infected donors and tissue explants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project relies on:

        -  our expertise of HIV in semen and male genital tract and our experience in organotypic
           cultures;

        -  a network of infectious diseases and reproductive biology clinicians to collect, analyze
           and process seminal cells and seminal plasma from HIV+ donors;

        -  the expertise in confocal microscopy and ex vivo colo-rectal model. State of the art
           culture of colo-rectal tissues, primary cell culture and infection, confocal microscopy,
           flow cytometry, Polymerase Chain Reaction and Luminex assays for cytokine measurements
           will be the methodologies primarily used in this project.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize seminal HIV infected cells.</measure>
    <time_frame>1 years</time_frame>
    <description>Macrophages and CD4+ T lymphocytes characterization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the potential of seminal HIV infected cells migration and adhesion.</measure>
    <time_frame>1 years</time_frame>
    <description>Assess the potential of seminal macrophages and CD4 T cells to adhere and transmigrate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the efficiency of seminal cell associated infection.</measure>
    <time_frame>1 years</time_frame>
    <description>The efficiency of seminal cell associated infection will be determinated in the colo-rectal explants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify molecules expressed and involved in seminal cell adhesion and transmigration.</measure>
    <time_frame>1 years</time_frame>
    <description>Identify key adhesion molecules expressed by seminal leucocytes and epithelial cells involved in seminal cell adhesion/transmigration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify seminal and mucosal molecules mediating seminal cell translocation.</measure>
    <time_frame>1 years</time_frame>
    <description>Seminal and mucosal soluble molecules mediating seminal cell translocation will be characterized (passive diffusion or active transmigration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of seminal plasma/cells exposure on mucosal immune cell.</measure>
    <time_frame>1 years</time_frame>
    <description>Mucosal immune cell activation, trafficking and the factors involved, will be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>HIV-1 infected patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood sample and sperm sample are collected</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>A sample of HIV-1 infected patients's blood is collected</description>
    <arm_group_label>HIV-1 infected patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sperm sample</intervention_name>
    <description>A sample of HIV-1 infected patients's sperm is collected</description>
    <arm_group_label>HIV-1 infected patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected patients who have never been treated by antiretroviral therapy

          -  Signature of informed consent

          -  Affiliation to social service

        Exclusion Criteria:

          -  Patients' general condition not allowing protocol follow-up

          -  Patients with an ejaculation disorder

          -  Patients unable to perform semen sampling

          -  Patients with chemotherapy or radiotherapy antecedents

          -  Patients with very severe oligospermia (≤1million/mL of spermatozoa)

          -  Patients with active genital infection

          -  Protected subjects
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Dejucq-Rainsford, PhD</last_name>
    <role>Study Director</role>
    <affiliation>IRSET</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louis Bujan, Pr</last_name>
    <phone>05 61 77 10 46</phone>
    <phone_ext>33</phone_ext>
    <email>bujan.l@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CECOS Bretagne Rennes</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Célia Ravel, Pr</last_name>
      <phone>0299265911</phone>
      <phone_ext>33</phone_ext>
      <email>celia.ravel@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Raïsse Aperano-Mas, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cédric Arvieux, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guilhem Jouve, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Célia Ravel, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CECOS Hôpital Paule de Viguier</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrénées</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Bujan, Pr</last_name>
      <phone>05 61 77 10 46</phone>
      <phone_ext>33</phone_ext>
      <email>bujan.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Myriam Daudin, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis Bujan, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CECOS Paris Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Patrat, Pr</last_name>
      <phone>01 40 25 88 84</phone>
      <phone_ext>33</phone_ext>
      <email>catherine.patrat@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Astrid Llabador-de-Royer, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Patrat, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Roulet V, Satie AP, Ruffault A, Le Tortorec A, Denis H, Guist'hau O, Patard JJ, Rioux-Leclerq N, Gicquel J, Jégou B, Dejucq-Rainsford N. Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro. Am J Pathol. 2006 Dec;169(6):2094-103.</citation>
    <PMID>17148672</PMID>
  </reference>
  <reference>
    <citation>Le Tortorec A, Le Grand R, Denis H, Satie AP, Mannioui K, Roques P, Maillard A, Daniels S, Jégou B, Dejucq-Rainsford N. Infection of semen-producing organs by SIV during the acute and chronic stages of the disease. PLoS One. 2008 Mar 12;3(3):e1792. doi: 10.1371/journal.pone.0001792.</citation>
    <PMID>18347738</PMID>
  </reference>
  <reference>
    <citation>Le Tortorec A, Satie AP, Denis H, Rioux-Leclercq N, Havard L, Ruffault A, Jégou B, Dejucq-Rainsford N. Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo. Retrovirology. 2008 Dec 31;5:119. doi: 10.1186/1742-4690-5-119.</citation>
    <PMID>19117522</PMID>
  </reference>
  <reference>
    <citation>Houzet L, Matusali G, Dejucq-Rainsford N. Origins of HIV-infected leukocytes and virions in semen. J Infect Dis. 2014 Dec 15;210 Suppl 3:S622-30. doi: 10.1093/infdis/jiu328. Review.</citation>
    <PMID>25414416</PMID>
  </reference>
  <reference>
    <citation>Camus C, Matusali G, Bourry O, Mahe D, Aubry F, Bujan L, Pasquier C, Massip P, Ravel C, Zirafi O, Munch J, Roan NR, Pineau C, Dejucq-Rainsford N. Comparison of the effect of semen from HIV-infected and uninfected men on CD4+ T-cell infection. AIDS. 2016 May 15;30(8):1197-208. doi: 10.1097/QAD.0000000000001048.</citation>
    <PMID>26854806</PMID>
  </reference>
  <reference>
    <citation>Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH. Targeting Trojan Horse leukocytes for HIV prevention. AIDS. 2010 Jan 16;24(2):163-87. doi: 10.1097/QAD.0b013e32833424c8. Review.</citation>
    <PMID>20010071</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Colo-rectal transmission</keyword>
  <keyword>seminal plasma</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The duplicated part of the CRFs will then be sent to Mrs DEJUC at the IRST in Rennes, the remaining part will be kept in the investigating center.
All the data of the study transcribed by the investigator in the CRFs will be transmitted electronically to the person in charge of the data of the INSERM / IRSET 1085 unit. Upon receipt, the data will be entered simply by typing and re-reading on the Excel spreadsheet. The files will be locked by password and backed up daily with storage for 3 months on the server of the INSERM 1085 unit managed by the IT department of the University of Rennes 1. The set Data is saved every evening, with storage for 4 weeks, then archived monthly on tape.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

